Market Research Report
NORTH AMERICA BOTANICAL & PLANT DERIVATIVE DRUG MARKET FORECAST 2018-2026
|Published by||Inkwood Research||Product code||568465|
|Published||Content info||92 Pages
Delivery time: 1-2 business days
|NORTH AMERICA BOTANICAL & PLANT DERIVATIVE DRUG MARKET FORECAST 2018-2026|
|Published: February 12, 2018||Content info: 92 Pages||
The North America botanical and plant derivative drug market is predicted to expand at a CAGR of 7.57%, for the forecast period of 2018-2026.
Several noted vendors in North America are increasingly promoting the deployment of botanical drugs and products as key dietary supplements. However, only a few products have been approved by the United States Food and Drug Administration (FDA) for deployment as prescription drugs. The increasing approval by FDA for botanical drugs and their escalating usage in the regions are presenting the market with potential growth opportunities.
Some of the major players in the market are Glenmark Pharmaceuticals Ltd, Bayer Healthcare Llc, Analyticon Discovery Gmbh, Piramal Phytocare Ltd, GlaxoSmithKline, Abbott Laboratories, Bionova, Tasly Pharmaceuticals Inc, Eli Lilly And Company, Medigene, Novartis International Ag, Boehringer Ingelheim, and Ranbaxy Laboratories Ltd (Acquired By Sun Pharmaceuticals Ltd).